Efficacy and safety of Viltepso® in Duchenne muscular dystrophy: review of clinical studies

Cover Page

Cite item

Full Text

Abstract

The author presents a literature review on the safety and efficacy of antisense oligonucleotides in the treatment of Duchenne muscular dystrophy using the exon skipping method using Viltepso® (viltolarsen), the only drug of this class registered in Russia, as an example. The analysis of international publications on clinical trials showed a high level of efficacy and safety of Viltepso®. This article, among other things, describes a 4-year clinical trial of viltolarsen. To date, this is the longest clinical trial of drugs of this group for the treatment of Duchenne muscular dystrophy. At the same time, it should not be forgotten that any pathogenetic therapy for Duchenne muscular dystrophy does not cure, but only slows down the progression of the disease, transferring it to a clinical form similar to Becker muscular dystrophy, provided that therapy is started early. In this regard, none of the currently available pathogenetic therapy can be considered as a monotherapy for the disease. Pathogenetic therapy will be most effective and will bring the desired results only with timely initiation of treatment and in combination with glucocorticosteroid therapy, symptomatic therapy and medical rehabilitation.

About the authors

V. M. Suslov

Department of Rehabilitation, Faculty of Postgraduate and Further Professional Education, Saint Petersburg State Pediatric Medical University, Ministry of Health of Russia

Author for correspondence.
Email: vms.92@mail.ru
ORCID iD: 0000-0002-5903-8789

Vasilyy Mikhaylovich Suslov

2 Litovskaya St., Saint Petersburg 194100

Russian Federation

D. I. Rudenko

Department of Rehabilitation, Faculty of Postgraduate and Further Professional Education, Saint Petersburg State Pediatric Medical University, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0009-0008-2770-6755

2 Litovskaya St., Saint Petersburg 194100

Russian Federation

References

  1. Duchenne muscular dystrophy. Becker muscular dystrophy. Clinical guidelines. Moscow: Ministry of Health of Russia, 2023. (In Russ.).
  2. Polyakov A.V. Modern diagnostic capabilities of Duchenne muscular dystrophy. VI All-Russian scientific and practical congress with international participation “Orphan diseases”, 2024. (In Russ.).
  3. Angulski A.B.B, Hosny N., Cohe H. et al. Duchenne muscular dystrophy: Disease mechanism and therapeutic strategies. Front Physiol 2023;14:1183101. doi: 10.3389/fphys.2023.1183101
  4. Birnkrant D.J., Bushby K., Bann C.M. et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol 2018;17(3):251–67. doi: 10.1016/S1474-4422(18)30024-3
  5. Clemens P.R., Rao V.K., Connolly A.M. et al. Efficacy and safety of viltolarsen in boys with Duchenne muscular dystrophy: Results from the phase 2, open-label, 4-year extension study. J Neuromuscul Dis 2023;10(3):439–47. doi: 10.3233/JND-221656
  6. Clemens P.R., Rao V.K., ConnollyA.M. et al. Long-term functional efficacy and safety of viltolarsen in patients with Duchenne muscular dystrophy. J Neuromuscular Dis 2022;9:493–501. doi: 10.3233/JND-220811
  7. Clemens P.R., Rao V.K., Connolly A.M. et al. Safety, tolerability, and efficacy of viltolarsen in boys with Duchenne muscular dystrophy amenable to exon 53 skipping: A phase 2 randomized clinical trial. JAMA Neurol 2020;77(8):982–91. doi: 10.1001/jamaneurol.2020.1264
  8. FDA Approves Targeted Treatment for Rare Duchenne Muscular Dystrophy Mutation. Available at: https://www.fda.gov/newsevents/press-announcements/fda-approves-targeted-treatmentrare-duchenne-muscular-dystrophy-mutation.
  9. Gissel H. The role of Ca2+ in muscle cell damage. Ann NY Acad Sci 2005;1066:166–80. doi: 10.1196/annals.1363.013
  10. Hoffman E.P., Fischbeck K.H., Brown R.H. et al. Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne’s or Becker’s muscular dystrophy. N Engl J Med 1988;318(21):1363–8. doi: 10.1056/NEJM198805263182104
  11. Iwata Y., Katanosaka Y., Shijun Z. et al. Protective effects of Ca2+ handling drugs against abnormal Ca2+ homeostasis and cell damage in myopathic skeletal muscle cells. Biochem Pharmacol 2005;70(5):740–51. doi: 10.1016/j.bcp.2005.05.034
  12. Flanigan K.M. Duchenne and Becker muscular dystrophies. Neurol Clin 2014;32:671–88. doi: 10.1016/j.ncl.2014.05.002
  13. Komaki H., Nagata T., Saito T. et al. Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy. Sci Transl Med 2018;10(437):eaan0713. doi: 10.1126/scitranslmed.aan0713
  14. Researcher View. Safety and Dose Finding Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD). Available at: https://clinicaltrials.gov/study/NCT02740972?tab=table.
  15. Roshmi R.R., Yokota T. Viltolarsen for the treatment of Duchenne muscular dystrophy. Drugs Today (Barc) 2019;55(10):627–39. doi: 10.1358/dot.2019.55.10.3045038
  16. Study Details. Exploratory Study of NS-065/NCNP-01 in DMD. Available at: https://clinicaltrials.gov/study/NCT02081625?intr=NS-065%2FNCNP-01&rank=2.
  17. Study Details. Extension Study of NS-065/NCNP-01 in Boys with Duchenne Muscular Dystrophy (DMD). Available at: https://clinicaltrials.gov/study/NCT03167255?term=NCT0316725 5&rank=1.
  18. Van den Bergen J.C., Wokke B.H., Janson A.A. et al. Dystrophin levels and clinical severity in Becker muscular dystrophy patients. J Neurol Neurosurg Psychiatry 2014;85(7):747–53. doi: 10.1136/jnnp-2013-306350

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 22926 от  12.01.2006.